APO Research
Talk to an analyst

APO RESEARCH · REPORT

Kidney Fibrosis Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Kidney Fibrosis Drugs Market Outlook and Growth Opportunities 2026

22 December 2025199 pages

Choose your research edition.

Industry ResearchKidney Fibrosis Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Kidney Fibrosis Drugs Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Kidney Fibrosis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Kidney Fibrosis Drugs Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Kidney Fibrosis Drugs Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Kidney Fibrosis Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Kidney Fibrosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Kidney Fibrosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Kidney Fibrosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Kidney Fibrosis Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Kidney Fibrosis Drugs market include Merck and Co, F. Hoffman-La Roche, Pfizer Inc, ProMetic Life-Sciences Inc, La Jolla Pharmaceutical Company, InterMune Inc, Genzyme Corporation, Galectin Therapeutics and BioLine Rx, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Kidney Fibrosis Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Kidney Fibrosis Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Kidney Fibrosis Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Kidney Fibrosis Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Kidney Fibrosis Drugs Segment by Company

Merck and Co

F. Hoffman-La Roche

Pfizer Inc

ProMetic Life-Sciences Inc

La Jolla Pharmaceutical Company

InterMune Inc

Genzyme Corporation

Galectin Therapeutics

BioLine Rx

Kidney Fibrosis Drugs Segment by Type

Angiotensin Converting Enzyme (ACE) Inhibitors

Angiotensin II Receptor Blockers (ARBs)

Renin Inhibitors

Vasopeptidase Inhibitors

Pirfenidone

Kidney Fibrosis Drugs Segment by Application

Chronic Kidney Diseases

Kidney Cancer Treatment

Others

Kidney Fibrosis Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Kidney Fibrosis Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Kidney Fibrosis Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Kidney Fibrosis Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Kidney Fibrosis Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Kidney Fibrosis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Kidney Fibrosis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Kidney Fibrosis Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Kidney Fibrosis Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Kidney Fibrosis Drugs industry.

Chapter 3: Detailed analysis of Kidney Fibrosis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Kidney Fibrosis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Kidney Fibrosis Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Kidney Fibrosis Drugs Industry Trends Table 2. Kidney Fibrosis Drugs Industry Drivers Table 3. Kidney Fibrosis Drugs Industry Opportunities and Challenges Table 4. Kidney Fibrosis Drugs Industry Restraints Table 5. Global Kidney Fibrosis Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Kidney Fibrosis Drugs Revenue Share by Company (2021-2026) Table 7. Global Kidney Fibrosis Drugs Sales Volume by Company (k units) & (2021-2026) Table 8. Global Kidney Fibrosis Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Kidney Fibrosis Drugs Average Price (US$/unit) of Company (2021-2026) Table 10. Global Kidney Fibrosis Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Kidney Fibrosis Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Kidney Fibrosis Drugs Company, Product Type & Application Table 13. Global Kidney Fibrosis Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Kidney Fibrosis Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Angiotensin Converting Enzyme (ACE) Inhibitors Table 18. Significant Companies of Angiotensin II Receptor Blockers (ARBs) Table 19. Significant Companies of Renin Inhibitors Table 20. Significant Companies of Vasopeptidase Inhibitors Table 21. Significant Companies of Pirfenidone Table 22. Global Kidney Fibrosis Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 23. Global Kidney Fibrosis Drugs Sales Volume by Type (2021-2026) & (k units) Table 24. Global Kidney Fibrosis Drugs Sales Volume by Type (2027-2032) & (k units) Table 25. Global Kidney Fibrosis Drugs Sales Volume Share by Type (2021-2026) Table 26. Global Kidney Fibrosis Drugs Sales Volume Share by Type (2027-2032) Table 27. Global Kidney Fibrosis Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Kidney Fibrosis Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Kidney Fibrosis Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Kidney Fibrosis Drugs Sales Value Share by Type (2021-2026) Table 31. Global Kidney Fibrosis Drugs Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Chronic Kidney Diseases Table 33. Significant Companies of Kidney Cancer Treatment Table 34. Significant Companies of Others Table 35. Global Kidney Fibrosis Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Kidney Fibrosis Drugs Sales Volume by Application (2021-2026) & (k units) Table 37. Global Kidney Fibrosis Drugs Sales Volume by Application (2027-2032) & (k units) Table 38. Global Kidney Fibrosis Drugs Sales Volume Share by Application (2021-2026) Table 39. Global Kidney Fibrosis Drugs Sales Volume Share by Application (2027-2032) Table 40. Global Kidney Fibrosis Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Kidney Fibrosis Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Kidney Fibrosis Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Kidney Fibrosis Drugs Sales Value Share by Application (2021-2026) Table 44. Global Kidney Fibrosis Drugs Sales Value Share by Application (2027-2032) Table 45. Global Kidney Fibrosis Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 46. Global Kidney Fibrosis Drugs Sales by Region (2021-2026) & (k units) Table 47. Global Kidney Fibrosis Drugs Sales Market Share by Region (2021-2026) Table 48. Global Kidney Fibrosis Drugs Sales by Region (2027-2032) & (k units) Table 49. Global Kidney Fibrosis Drugs Sales Market Share by Region (2027-2032) Table 50. Global Kidney Fibrosis Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Kidney Fibrosis Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Kidney Fibrosis Drugs Sales Value Share by Region (2021-2026) Table 53. Global Kidney Fibrosis Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Kidney Fibrosis Drugs Sales Value Share by Region (2027-2032) Table 55. Global Kidney Fibrosis Drugs Market Average Price (US$/unit) by Region (2021-2026) Table 56. Global Kidney Fibrosis Drugs Market Average Price (US$/unit) by Region (2027-2032) Table 57. Global Kidney Fibrosis Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 58. Global Kidney Fibrosis Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Kidney Fibrosis Drugs Sales by Country (2021-2026) & (k units) Table 60. Global Kidney Fibrosis Drugs Sales Market Share by Country (2021-2026) Table 61. Global Kidney Fibrosis Drugs Sales by Country (2027-2032) & (k units) Table 62. Global Kidney Fibrosis Drugs Sales Market Share by Country (2027-2032) Table 63. Global Kidney Fibrosis Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Kidney Fibrosis Drugs Sales Value Market Share by Country (2021-2026) Table 65. Global Kidney Fibrosis Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Kidney Fibrosis Drugs Sales Value Market Share by Country (2027-2032) Table 67. Merck and Co Company Information Table 68. Merck and Co Business Overview Table 69. Merck and Co Kidney Fibrosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 70. Merck and Co Kidney Fibrosis Drugs Product Portfolio Table 71. Merck and Co Recent Development Table 72. F. Hoffman-La Roche Company Information Table 73. F. Hoffman-La Roche Business Overview Table 74. F. Hoffman-La Roche Kidney Fibrosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. F. Hoffman-La Roche Kidney Fibrosis Drugs Product Portfolio Table 76. F. Hoffman-La Roche Recent Development Table 77. Pfizer Inc Company Information Table 78. Pfizer Inc Business Overview Table 79. Pfizer Inc Kidney Fibrosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Pfizer Inc Kidney Fibrosis Drugs Product Portfolio Table 81. Pfizer Inc Recent Development Table 82. ProMetic Life-Sciences Inc Company Information Table 83. ProMetic Life-Sciences Inc Business Overview Table 84. ProMetic Life-Sciences Inc Kidney Fibrosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. ProMetic Life-Sciences Inc Kidney Fibrosis Drugs Product Portfolio Table 86. ProMetic Life-Sciences Inc Recent Development Table 87. La Jolla Pharmaceutical Company Company Information Table 88. La Jolla Pharmaceutical Company Business Overview Table 89. La Jolla Pharmaceutical Company Kidney Fibrosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. La Jolla Pharmaceutical Company Kidney Fibrosis Drugs Product Portfolio Table 91. La Jolla Pharmaceutical Company Recent Development Table 92. InterMune Inc Company Information Table 93. InterMune Inc Business Overview Table 94. InterMune Inc Kidney Fibrosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. InterMune Inc Kidney Fibrosis Drugs Product Portfolio Table 96. InterMune Inc Recent Development Table 97. Genzyme Corporation Company Information Table 98. Genzyme Corporation Business Overview Table 99. Genzyme Corporation Kidney Fibrosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. Genzyme Corporation Kidney Fibrosis Drugs Product Portfolio Table 101. Genzyme Corporation Recent Development Table 102. Galectin Therapeutics Company Information Table 103. Galectin Therapeutics Business Overview Table 104. Galectin Therapeutics Kidney Fibrosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. Galectin Therapeutics Kidney Fibrosis Drugs Product Portfolio Table 106. Galectin Therapeutics Recent Development Table 107. BioLine Rx Company Information Table 108. BioLine Rx Business Overview Table 109. BioLine Rx Kidney Fibrosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. BioLine Rx Kidney Fibrosis Drugs Product Portfolio Table 111. BioLine Rx Recent Development Table 112. Key Raw Materials Table 113. Raw Materials Key Suppliers Table 114. Kidney Fibrosis Drugs Distributors List Table 115. Kidney Fibrosis Drugs Customers List Table 116. Research Programs/Design for This Report Table 117. Authors List of This Report Table 118. Secondary Sources Table 119. Primary Sources List of Figures Figure 1. Kidney Fibrosis Drugs Product Image Figure 2. Global Kidney Fibrosis Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Kidney Fibrosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Kidney Fibrosis Drugs Sales (2021-2032) & (k units) Figure 5. Global Kidney Fibrosis Drugs Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Kidney Fibrosis Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Angiotensin Converting Enzyme (ACE) Inhibitors Image Figure 10. Angiotensin II Receptor Blockers (ARBs) Image Figure 11. Renin Inhibitors Image Figure 12. Vasopeptidase Inhibitors Image Figure 13. Pirfenidone Image Figure 14. Global Kidney Fibrosis Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Kidney Fibrosis Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Kidney Fibrosis Drugs Sales Volume Share by Type (2021-2032) Figure 17. Global Kidney Fibrosis Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Kidney Fibrosis Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Kidney Fibrosis Drugs Sales Value Share by Type (2021-2032) Figure 20. Chronic Kidney Diseases Image Figure 21. Kidney Cancer Treatment Image Figure 22. Others Image Figure 23. Global Kidney Fibrosis Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Kidney Fibrosis Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Kidney Fibrosis Drugs Sales Volume Share by Application (2021-2032) Figure 26. Global Kidney Fibrosis Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Kidney Fibrosis Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Kidney Fibrosis Drugs Sales Value Share by Application (2021-2032) Figure 29. Global Kidney Fibrosis Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 30. Global Kidney Fibrosis Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Kidney Fibrosis Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Kidney Fibrosis Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Kidney Fibrosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. North America Kidney Fibrosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Kidney Fibrosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Kidney Fibrosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Kidney Fibrosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Kidney Fibrosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Kidney Fibrosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. South America Kidney Fibrosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Kidney Fibrosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Kidney Fibrosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Kidney Fibrosis Drugs Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Kidney Fibrosis Drugs Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Angiotensin Converting Enzyme (ACE) Inhibitors
  • Angiotensin II Receptor Blockers (ARBs)
  • Renin Inhibitors
  • Vasopeptidase Inhibitors
  • Pirfenidone
Applications
  • Chronic Kidney Diseases
  • Kidney Cancer Treatment
  • Others
Companies covered
  • Merck and Co
  • F. Hoffman-La Roche
  • Pfizer Inc
  • ProMetic Life-Sciences Inc
  • La Jolla Pharmaceutical Company
  • InterMune Inc
  • Genzyme Corporation
  • Galectin Therapeutics
  • BioLine Rx

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Kidney Fibrosis Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Kidney Fibrosis Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Kidney Fibrosis Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Kidney Fibrosis Drugs Market Dynamics
  1. 2.1 Kidney Fibrosis Drugs Industry Trends
  2. 2.2 Kidney Fibrosis Drugs Industry Drivers
  3. 2.3 Kidney Fibrosis Drugs Industry Opportunities and Challenges
  4. 2.4 Kidney Fibrosis Drugs Industry Restraints
3 Kidney Fibrosis Drugs Market by Company
  1. 3.1 Global Kidney Fibrosis Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Kidney Fibrosis Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Kidney Fibrosis Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Kidney Fibrosis Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Kidney Fibrosis Drugs Company Ranking (2024-2026)
  6. 3.6 Global Kidney Fibrosis Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Kidney Fibrosis Drugs Company Product Type and Application
  8. 3.8 Global Kidney Fibrosis Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Kidney Fibrosis Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Kidney Fibrosis Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Kidney Fibrosis Drugs Market by Type
  1. 4.1 Kidney Fibrosis Drugs Type Introduction
  2. 4.1.1 Angiotensin Converting Enzyme (ACE) Inhibitors
  3. 4.1.2 Angiotensin II Receptor Blockers (ARBs)
  4. 4.1.3 Renin Inhibitors
  5. 4.1.4 Vasopeptidase Inhibitors
  6. 4.1.5 Pirfenidone
  7. 4.2 Global Kidney Fibrosis Drugs Sales Volume by Type
  8. 4.2.1 Global Kidney Fibrosis Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Kidney Fibrosis Drugs Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Kidney Fibrosis Drugs Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Kidney Fibrosis Drugs Sales Value by Type
  12. 4.3.1 Global Kidney Fibrosis Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Kidney Fibrosis Drugs Sales Value by Type (2021-2032)
  14. 4.3.3 Global Kidney Fibrosis Drugs Sales Value Share by Type (2021-2032)
5 Kidney Fibrosis Drugs Market by Application
  1. 5.1 Kidney Fibrosis Drugs Application Introduction
  2. 5.1.1 Chronic Kidney Diseases
  3. 5.1.2 Kidney Cancer Treatment
  4. 5.1.3 Others
  5. 5.2 Global Kidney Fibrosis Drugs Sales Volume by Application
  6. 5.2.1 Global Kidney Fibrosis Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Kidney Fibrosis Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Kidney Fibrosis Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Kidney Fibrosis Drugs Sales Value by Application
  10. 5.3.1 Global Kidney Fibrosis Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Kidney Fibrosis Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Kidney Fibrosis Drugs Sales Value Share by Application (2021-2032)
6 Kidney Fibrosis Drugs Regional Sales and Value Analysis
  1. 6.1 Global Kidney Fibrosis Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Kidney Fibrosis Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Kidney Fibrosis Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Kidney Fibrosis Drugs Sales by Region (2027-2032)
  5. 6.3 Global Kidney Fibrosis Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Kidney Fibrosis Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Kidney Fibrosis Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Kidney Fibrosis Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Kidney Fibrosis Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Kidney Fibrosis Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Kidney Fibrosis Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Kidney Fibrosis Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Kidney Fibrosis Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Kidney Fibrosis Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Kidney Fibrosis Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Kidney Fibrosis Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Kidney Fibrosis Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Kidney Fibrosis Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Kidney Fibrosis Drugs Sales Value Share by Country, 2025 VS 2032
7 Kidney Fibrosis Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Kidney Fibrosis Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Kidney Fibrosis Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Kidney Fibrosis Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Kidney Fibrosis Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Kidney Fibrosis Drugs Sales by Country (2027-2032)
  6. 7.4 Global Kidney Fibrosis Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Kidney Fibrosis Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Kidney Fibrosis Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Kidney Fibrosis Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Kidney Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Kidney Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck and Co
  2. 8.1.1 Merck and Co Company Information
  3. 8.1.2 Merck and Co Business Overview
  4. 8.1.3 Merck and Co Kidney Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Merck and Co Kidney Fibrosis Drugs Product Portfolio
  6. 8.1.5 Merck and Co Recent Developments
  7. 8.2 F. Hoffman-La Roche
  8. 8.2.1 F. Hoffman-La Roche Company Information
  9. 8.2.2 F. Hoffman-La Roche Business Overview
  10. 8.2.3 F. Hoffman-La Roche Kidney Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 F. Hoffman-La Roche Kidney Fibrosis Drugs Product Portfolio
  12. 8.2.5 F. Hoffman-La Roche Recent Developments
  13. 8.3 Pfizer Inc
  14. 8.3.1 Pfizer Inc Company Information
  15. 8.3.2 Pfizer Inc Business Overview
  16. 8.3.3 Pfizer Inc Kidney Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Inc Kidney Fibrosis Drugs Product Portfolio
  18. 8.3.5 Pfizer Inc Recent Developments
  19. 8.4 ProMetic Life-Sciences Inc
  20. 8.4.1 ProMetic Life-Sciences Inc Company Information
  21. 8.4.2 ProMetic Life-Sciences Inc Business Overview
  22. 8.4.3 ProMetic Life-Sciences Inc Kidney Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 ProMetic Life-Sciences Inc Kidney Fibrosis Drugs Product Portfolio
  24. 8.4.5 ProMetic Life-Sciences Inc Recent Developments
  25. 8.5 La Jolla Pharmaceutical Company
  26. 8.5.1 La Jolla Pharmaceutical Company Company Information
  27. 8.5.2 La Jolla Pharmaceutical Company Business Overview
  28. 8.5.3 La Jolla Pharmaceutical Company Kidney Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 La Jolla Pharmaceutical Company Kidney Fibrosis Drugs Product Portfolio
  30. 8.5.5 La Jolla Pharmaceutical Company Recent Developments
  31. 8.6 InterMune Inc
  32. 8.6.1 InterMune Inc Company Information
  33. 8.6.2 InterMune Inc Business Overview
  34. 8.6.3 InterMune Inc Kidney Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 InterMune Inc Kidney Fibrosis Drugs Product Portfolio
  36. 8.6.5 InterMune Inc Recent Developments
  37. 8.7 Genzyme Corporation
  38. 8.7.1 Genzyme Corporation Company Information
  39. 8.7.2 Genzyme Corporation Business Overview
  40. 8.7.3 Genzyme Corporation Kidney Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Genzyme Corporation Kidney Fibrosis Drugs Product Portfolio
  42. 8.7.5 Genzyme Corporation Recent Developments
  43. 8.8 Galectin Therapeutics
  44. 8.8.1 Galectin Therapeutics Company Information
  45. 8.8.2 Galectin Therapeutics Business Overview
  46. 8.8.3 Galectin Therapeutics Kidney Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Galectin Therapeutics Kidney Fibrosis Drugs Product Portfolio
  48. 8.8.5 Galectin Therapeutics Recent Developments
  49. 8.9 BioLine Rx
  50. 8.9.1 BioLine Rx Company Information
  51. 8.9.2 BioLine Rx Business Overview
  52. 8.9.3 BioLine Rx Kidney Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 BioLine Rx Kidney Fibrosis Drugs Product Portfolio
  54. 8.9.5 BioLine Rx Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Kidney Fibrosis Drugs Value Chain Analysis
  2. 9.1.1 Kidney Fibrosis Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Kidney Fibrosis Drugs Sales Mode & Process
  6. 9.2 Kidney Fibrosis Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Kidney Fibrosis Drugs Distributors
  9. 9.2.3 Kidney Fibrosis Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst